• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Teladoc Health (TDOC) Cuts Revenue Outlook, Is Integrated Care Enough To Support Fair Value?

    Simply Wall St·08/29/2026 08:17:34
    Listen to the news

    Teladoc Health (TDOC) is back in focus after its second quarter 2026 report. The company showed stronger Integrated Care results, weaker BetterHelp performance and a cut to full year revenue guidance, alongside expectations for margin improvement.

    Teladoc Health’s latest results land after a sharp reset in the share price, with the 30 day share price return down 29.19% and the year to date share price return down 7.80%. The 1 year total shareholder return has fallen 15.91% and the 5 year total shareholder return has declined 95.50%, signalling that recent optimism around Integrated Care has not yet reversed the longer term loss of momentum.

    Compare Teladoc Health’s reset with other healthcare stocks that have also been repriced recently by scanning our hand picked 44 high quality undervalued stocks with solid cash flows and stronger balance sheets.

    Bulls point to Teladoc Health’s Integrated Care progress and improving margins. Bears focus on BetterHelp weakness, a revenue guidance cut and multi year share price losses. Which side does the current valuation actually support next?

    Most Popular Narrative: 56.7% Undervalued

    According to the most followed Teladoc Health narrative, a fair value of $15.00 sits well above the recent $6.50 close, which frames today’s debate around the stock very differently.

    Despite the market narrative of a failing pandemic stock, Teladoc’s underlying financial engine tells a radically different story:

    * Solid Positive Free Cash Flow (FCF): Unlike cash-burning biotech or tech peers, Teladoc generated $166.9M in FCF in 2025 and is guided to deliver $130M to $170M in FCF for FY2026.

    Read the complete narrative. Read the complete narrative.

    The valuation in that narrative leans heavily on free cash flow strength, a higher future margin profile and a revenue mix shift toward insurance backed mental health. Curious which specific assumptions support a fair value more than double today’s share price and how the discount rate fits into that story.

    Result: Fair Value of $15.00 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Teladoc Health still faces pressure if the BetterHelp insurance pivot stalls, or if telehealth competitors keep tightening pricing and customer acquisition conditions.

    Find out about the key risks to this Teladoc Health narrative.

    Next Steps

    With Teladoc Health attracting both concern and optimism, it may be useful to act promptly and review the facts yourself. Consider the balance of potential upside and downside in the 3 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Teladoc Health?

    If Teladoc Health has your attention, do not stop there. Use the Simply Wall Street Screener to uncover other opportunities that might better fit your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.